Published online Feb 18, 2023. doi: 10.5312/wjo.v14.i2.55
Peer-review started: November 19, 2022
First decision: December 13, 2022
Revised: December 22, 2022
Accepted: January 19, 2023
Article in press: January 19, 2023
Published online: February 18, 2023
Processing time: 90 Days and 8.4 Hours
There has been an increasing incidence of fungal infections in recent years. Rarely joints are also affected by fungal infections. Mainly, these infections develop in prosthetic joints, but sometimes native joints are also involved. Candida infections are mostly reported, but patients may also develop infections secondary to non-Candida fungi, especially Aspergillus. Diagnosis and management of these infections is challenging and may involve multiple surgical interventions and prolonged antifungal therapy. Despite this, these infections are associated with high morbidity and mortality. This review described the clinical features, risk factors, and therapeutic interventions required to manage fungal arthritis.
Core Tip: Fungal arthritis and osteomyelitis are rare diseases, but their incidence is increasing with the rising prevalence of predisposing factors. Most infections are secondary to Candida spp., especially Candida albicans, but patients rarely develop infections secondary to other fungi, including Aspergillus, Histoplasma, Cryptococcus and Coccidioides. Fungal biomarkers may aid in rapid diagnosis in high-risk patients, but definitive diagnosis requires bone or synovial culture or biopsy. Surgical inter